
CDMOP
Healthcare · Biotechnology · $205.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 31, 2021 | Time not confirmed | 0.00 | 0.01 | — |
| Oct 31, 2020 | Time not confirmed | -0.07 | 0.01 | +114.3% |
| Jul 31, 2020 | Time not confirmed | -0.16 | 0.06 | +136.4% |
| Apr 30, 2020 | Time not confirmed | -0.04 | -0.10 | -159.0% |
| Jan 31, 2020 | Time not confirmed | -0.05 | -0.06 | -25.8% |
| Oct 31, 2019 | Time not confirmed | -0.03 | -0.03 | -11.0% |
| Jul 31, 2019 | Time not confirmed | -0.03 | -0.08 | -173.3% |
| Apr 30, 2019 | Time not confirmed | -0.07 | -0.02 | +78.4% |
| Jan 31, 2019 | Time not confirmed | -0.08 | -0.05 | +42.5% |
| Oct 31, 2018 | Time not confirmed | -0.13 | -0.06 | +50.2% |
| Jul 31, 2018 | Time not confirmed | -0.15 | -0.06 | +59.3% |
| Apr 30, 2018 | Time not confirmed | -0.14 | -0.14 | +3.4% |
| Jan 31, 2018 | Time not confirmed |
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug…
| -0.12 |
| -0.23 |
| -91.1% |